Clinical utility of muscle MR spectroscopy

Seminars in Musculoskeletal Radiology

Volumn 4, Issue 4, 2000, Pages 481-502

  Taylor, D J ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

31Phosphorus magnetic resonance spectroscopy; Exercise; Muscles; Myalgia; Myopathy

Indexed keywords

1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; ALCOHOL; BRYOSTATIN 1; MITOMYCIN C; NIFEDIPINE; PHOSPHORUS 31; PROTEIN KINASE C INHIBITOR; VELARESOL; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CELL PH; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DRUG EFFECT; ENERGY TRANSFER; EXERCISE; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; KIDNEY FAILURE; LONGITUDINAL STUDY; MALE; MITOCHONDRIAL MYOPATHY; MUSCLE METABOLISM; MYALGIA; MYOPATHY; MYOSITIS; MYOTONIC DYSTROPHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; SKELETAL MUSCLE; SYSTEMIC DISEASE;

ENERGY METABOLISM; EXERCISE; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MUSCLE, SKELETAL; MUSCULAR DISEASES; PHOSPHORUS ISOTOPES;

EID: 0034523134     PISSN: 10897860     EISSN: 1098898X     Source Type: Journal    
DOI: 10.1055/s-2000-13172     Document Type: Article

References (145)

1. Ageing: Effects on oxidative function of skeletal muscle in vivo
2. Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease
3. Investigation of human mitochondrial myopathies by phosphorus magnetic resonance spectroscopy
4. On the noninvasive measurement of intracellular free magnesium by 31P NMR spectroscopy
5. Deficit of brain and skeletal muscle bioenergetics and low brain magnesium in juvenile migraine: An in vivo 31P magnetic resonance spectroscopy interictal study
6. Phosphorus nuclear magnetic resonance spectroscopy: In vivo magnesium measurements in the skeletal muscle of normal subjects
7. Quantitative interpretation of bioenergetic data from 31P and 1H magnetic resonance spectroscopic studies of skeletal muscle: An analytical review
8. Genetic disease of mitochondrial function evaluated by NMR and NIR spectroscopy of skeletal tissue
9. Simultaneous in vivo measurements of HbO2 saturation and PCr kinetics after exercise in normal humans
10. Metabolic and myoelectrical effects of acute hypoxaemia during isometric contraction of forearm muscles in humans: A combined 31P-magnetic resonance spectroscopy-surface electromyogram (MRS-SEMG) study
11. Combined electromyography - 31P-magnetic resonance spectroscopy study of human muscle fatigue during static contraction
12. Simultaneous 31P NMR spectroscopy and EMG in exercising and recovering human skeletal muscle: Technical aspects
13. Discriminant factor analysis of 31P NMR spectroscopic data in myopathies
14. Bioenergetics of intact human muscle. A 31P nuclear magnetic resonance study
15. Bioenergetic heterogeneity of human mitochondrial myopathies: Phosphorus magnetic resonance spectroscopy study
16. Bioenergetics of skeletal muscle in mitochondrial myopathy
17. Metabolic recovery after exercise and the assessment of mitochondrial function in vivo in human skeletal muscle by means of 31P NMR
18. Heterogeneity of metabolic response to muscular exercise in humans. New criteria of invariance defined by in vivo phosphorus-31 NMR spectroscopy
19. In vivo assessment of mitochondrial functionality in human gastrocnemius muscle by 31P MRS. The role of pH in the evaluation of phosphocreatine and inorganic phosphate recoveries from exercise
20. Energetics of human muscle: Exercise-induced ATP depletion
21. Functional pools of oxidative and glycolytic fibers in human muscle observed by 31P magnetic resonance spectroscopy during exercise
22. Metabolic heterogeneity in human calf muscle during maximal exercise
23. Exercise-enhanced MR imaging of variations in forearm muscle anatomy and use: Importance in MR spectroscopy
24. Muscle metabolism in older subjects using 31P magnetic resonance spectroscopy
25. Endurance-trained and untrained skeletal muscle bioenergetics observed with magnetic resonance spectroscopy
26. Metabolic effects of training in humans: A 31P-MRS study
27. Metabolic changes in human muscle denervation: Topical 31P NMR spectroscopy studies
28. Human muscle cell denervation: The results of a 31-phosphorus magnetic resonance spectroscopy study
29. Application of 31P magnetic resonance spectroscopy to the study of athletic performance
30. Muscular sufficiency, serum protein, enzymes and bioenergetic studies (31-phosphorus magnetic resonance spectroscopy) in chronic malnutrition
31. In vivo skeletal muscle mitochondrial function in Leber's hereditary optic neuropathy assessed by 31P magnetic resonance spectroscopy
32. Leber's hereditary optic neuropathy: Genetic, biochemical, and phosphorus magnetic resonance spectroscopy study in an Italian family
33. Defective brain and muscle energy metabolism shown by in vivo 31P magnetic resonance spectroscopy in nonaffected carriers of 11778 mtDNA mutation
34. Leber's hereditary optic neuropathy: Biochemical effect of 11778/ND4 and 3460/ND1 mutations and correlation with the mitochondrial genotype
35. The influence of nuclear background on the biochemical expression of 3460 Leber's hereditary optic neuropathy
36. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia
37. Very low levels of the mt DNA A3243G mutation associated with mitochondrial dysfunction in vivo
38. In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondrial disease
39. 3 and C in a patient with a defect in electron transportb at complex 111 in skeletal muscle
40. MELAS syndrome with mitochondrial tRNA(Leu) (UUR) mutation: Correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin
41. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease
42. 31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies
43. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy
44. Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders
45. Effects of aerobic training in patients with mitochondrial myopathies
46. Examination of a case of suspected McArdle's syndrome by 31P nuclear magnetic resonance
47. Muscle energy metabolism in McArdle's syndrome by in vivo phosphorus magnetic resonance spectroscopy
48. Phosphourus NMR spectroscopy study of muscular enzyme deficiencies involving glycogenolysis and glycolysis
49. Biochemistry in vivo: An appraisal of clinical magnetic resonance spectroscopy
50. 31-P characterization of the metabolic anomalies associated with the lack of glycogen phosphorylase activity in human forearm muscle
51. 31P-MR spectroscopy in a case with associated multifocal encephalopathy
52. Impairment of muscle mitochondrial oxidative metabolism in McArdles's disease
53. 31P NMR study
54. Clinical use of nuclear magnetic resonance in the investigation of myopathy
55. Muscle energy metabolism in human phosphofructokinase deficiency as recorded by 31P nuclear magnetic resonance spectroscopy
56. Impaired aerobic glycolysis in muscle phosphofructokinase deficiency results in biphasic post-exercise phosphocreatine recovery in 31P magnetic resonance spectroscopy
57. Muscle metabolism during lactate infusion in human phosphofructokinase deficiency
58. Skeletal muscle disorders and associated factors that limit exercise performance
59. Late-onset muscle weakness in partial phosphofructokinase deficiency: A unique myopathy with vacuoles, abnormal mitochondria, and absence of the common exon 5/intron 5 junction point mutation
60. Partial block of glycolysis in late-onset phosphofructokinase deficiency myopathy
61. Characterization of the enzymatic defect in late-onset muscle phosphofructokinase deficiency. New subtype of glycogen storage disease type VII
62. Phosphorus magnetic resonance spectroscopy of partially blocked muscle glycolysis. An in vivo study of phosphoglycerate mutase deficiency
63. Muscle phosphoglycerate mutase (PGAM) deficiency in the first Caucasian patient: Biochemistry, muscle culture and 31P-MR spectroscopy
64. Improved energy kinetics following high protein diet in McArdle's syndrome. A 31P magnetic resonance spectroscopy study
65. A placebo-controlled crossover trial of creatine therapy in myophosphorylase deficiency (McArdle's disease)
66. 31P-NMR spectroscopy of skeletal muscle in Becker dystrophy and DMD/BMD carriers. Altered rate of phosphate transport
67. Topical magnetic resonance for the study of muscle metabolism in human myopathy
68. Cellular energetics of dystrophic muscle
69. Nuclear magnetic resonance studies of forearm muscle in Duchenne dystrophy
70. 31P NMR studies in Duchenne muscular dystrophy: Age-related metabolic changes
71. Skeletal muscle metabolism in myotonic dystrophy A 31P magnetic resonance spectroscopy study
72. Further impairment of muscle phosphate kinetics by lengthening exercise in DMD/BMD carriers. An in vivo 31P-NMR spectroscopy study
73. Reduced cytosolic acidification during exercise suggests defective glycolytic activity in skeletal muscle of patients with Becker muscular dystrophy. An in vivo 31P magnetic resonance spectroscopy study
74. Correlative MR imaging and 31P-MR spectroscopy study in sarcoglycan deficient limb girdle muscular dystrophy
75. Forearm P-31 nuclear magnetic resonance spectroscopy studies in oculopharyngeal muscular dystrophy
76. Quantitative analysis by 31P magnetic resonance spectroscopy of abnormal mitochondrial oxidation in skeletal muscle during recovery from exercise
77. Control of oxidative phosphorylation in rat muscle mitochondria: Implications for mitochondrial myopathies
78. Gylcolysis revisited
79. Skeletal muscle bioenergetics in myotonic dystrophy
80. Characterization of the myotonic dystrophy region predicts multiple protein isoform-encoding mRNAs
81. Structure and genomic sequence of the myotonic dystrophy (DM kinase) gene
82. Slower recovery of muscle phosphocreatine in malignant hyperthermiasusceptible individuals assessed by 31P-MR spectroscopy
83. 31Phosphorus magnetic resonance spectroscopy characterization of muscular metabolic anomalies in patients with malignant hyperthermia: Application to diagnosis
84. Metabolic response to exercise in malignant hyperthermia-sensitive patients measured by 31P magnetic resonance spectroscopy
85. A blinded comparison of noninvasive, in vivo phosphorus nuclear magnetic resonance spectroscopy and the in vitro halothane/caffeine contracture test in the evaluation of malignant hyperthermia susceptibility
86. Improved noninvasive diagnostic testing for malignant hyperthermia susceptibility from a combination of metabolites determined in vivo with 31P-magnetic resonance spectroscopy
87. In vitro 31P-magnetic resonance spectroscopy of muscle extracts in malignant hyperthermia-susceptible patients
88. Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis
89. MRI and 31P MRS demonstrate abnormal muscle efficiency and mitochondrial function in inflammatory myopathies, 4th International Congress of the World Muscle Society
90. Use of magnetic resonance imaging and P-31 magnetic resonance spectroscopy to detect and quantify muscle dysfunctior, in the amyopathic and myopathic variants of dermatomyositis
91. Dermatomyositis: Correlative MR imaging and P-31 MR spectroscopy for quantitative characterization of inflammatory disease
92. Microvascular changes in early and advanced dermatomyositis: A quantitative study
93. Polymyositis, dermatomyositis, and inclusionbody myositis
94. Inclusion body myositis and myopathies
95. Mitochondrial DNA deletions in inclusion body myositis
96. Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: A study of 56 patients
97. Normal in vivo skeletal muscle oxidative metabolism in sporadic inclusion body myositis assessed by 31P-magnetic resonance spectroscopy
98. Intracellular phosphates in inclusion body myositis - A 31P magnetic resonance spectroscopy study
99. Analysis of 31P MR spectroscopy data using artificial neural networks for longitudinal evaluation of muscle diseases: Dermatomyositis
100. Uraemic muscle metabolism at rest and during exercise
101. The effect of propionyl L-carnitine on skeletal muscle metabolism in renal failure
102. Bioenergetic effects of erythropoietin in skeletal muscle
103. Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure
104. Evaluation of energy metabolism in skeletal muscle of patients with heart failure with gated phosphorus-31 nuclear magnetic resonance
105. Skeletal muscle metabolism in patients with congestive heart failure: Relation to clinical severity and blood flow
106. Abnormalities in exercising skeletal muscle in congestive heart failure can be explained in terms of decreased mitochondrial ATP synthesis, reduced metabolic efficiency, and increased glycogenolysis
107. Interrelationship of oxidative metabolism and local perfusion demonstrated by NMR in human skeletal muscle
108. Local relation between oxidative metabolism and perfusion in leg muscles of patients with heart failure studied by magnetic resonance imaging and spectroscopy
109. Abnormalities of the skeletal muscle in hypertrophic cardiomyopathy. Spectroscopy using phosphorus-31 nuclear magnetic resonance
110. Abnormal skeletal muscle bioenergetics in familial hypertrophic cardiomyopathy
111. Skeletal muscle response to exercise training in congestive heart failure
112. Physical training improves skeletal muscle metabolism in patients with chronic heart failure
113. Effects of lowfrequency electrical stimulation of quadriceps and calf muscles in patients with chronic heart failure
114. Calf muscle mitochondrial and glycogenolytic ATP synthesis in patients with claudication due to peripheral vascular disease analysed using 31P magnetic resonance spectroscopy
115. Changes in energy metabolism of calf muscle in patients with intermittent claudication assessed by 31P magnetic resonance spectroscopy: A phase II open study
116. Muscle energy metabolism and nutritional status in patients with chronic obstructive pulmonary disease. A 31P magnetic resonance study
117. Skeletal muscle metabolism during exercise and recovery in patients with respiratory failure
118. Impairment of muscular metabolism in chronic respiratory failure. A human 31P MRS study
119. Metabolism and aerobic capacity of skeletal muscle in chronic respiratory failure related to chronic obstructive pulmonary disease
120. Skeletal muscle abnormalities in chronic obstructive lung disease with respiratory insufficiency. Value of P31 magnetic resonance spectroscopy
121. Cellular energetics in hypothyroid muscle
122. Energetic metabolism in hypothyroid skeletal muscle, as studied by phosphorus magnetic resonance spectroscopy
123. Effects of thyroid hormones on skeletal muscle bioenergetics. In vivo phosphorus-31 magnetic resonance spectroscopy study of humans and rats
124. Reduced metabolic efficiency of skeletal muscle energetics in hyperthyroid patients evidenced quantitatively by in vivo phosphorus-31 magnetic resonance spectroscopy
125. Effects of thyroid hormone treatment on 31PNMR spectroscopy of muscle and on nerve conduction studies in a patient with long-standing severe hypothyroidism
126. Evidence for abnormal Na+/H+ antiport activity detected by phosphorus nuclear magnetic resonance spectroscopy in exercising skeletal muscle of patients with essential hypertension
127. Excessive intracellular acidosis of skeletal muscle on exercise in a patient with a post-viral exhaustion/fatigue syndrome. A 31P nuclear magnetic resonance study
128. Skeletal muscle bioenergetics in the chronic fatigue syndrome
129. Chronic fatigue syndrome and skeletal muscle mitochondrial function
130. Reduced oxidative muscle metabolism in chronic fatigue syndrome
131. Heterogeneity in chronic fatigue syndrome: Evidence from magnetic resonance spectroscopy of muscle
132. Lack of association between fibromyalgia syndrome and abnormalities in muscle energy metabolism
133. 31P NMR spectroscopy and electromyography during exercise and recovery in patients with fibromyalgia
134. In vivo 31P magnetic resonance spectroscopy (MRS) of tender points in patients with primary fibromyalgia syndrome
135. Use of P-31 magnetic resonance spectroscopy to detect metabolic abnormalities in muscles of patients with fibromyalgia
136. A phase I study of the left-shifting agent BW12C79 plus mitomycin-C and the effect on the skeletal muscle metabolism using P31 magnetic resonance spectroscopy
137. Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: A 31P magnetic resonance spectroscopic study
138. Modulation of bryostatin 1 muscle toxicity by nifedipine: Effects on muscle metabolism and oxygen supply
139. Phase I trial of the selective mitochondrial toxin MKT 077 in chemoresistant solid tumours
140. 31P magnetic resonance spectroscopy suggests impaired mitochondrial function in AZT-treated HIV-infected patients
141. Metabolic abnormalities in skeletal muscle of patients receiving zidovudine therapy observed by 31P in vivo magnetic resonance spectroscopy
142. Studies on the inhibition of mitochondrial DNA replication by 3′-azido-3′-deoxythymidine and other dideoxynucleoside analogs which inhibit HIV-1 replication
143. Phosphorus nuclear magnetic resonance evidence of abnormal skeletal muscle metabolism in chronic alcoholics
144. Imaging and spectroscopy of muscle